Wells Fargo & Company Maia Biotechnology, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MAIA
# of Institutions
18Shares Held
1.47MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA566KShares$1.24 Million0.0% of portfolio
-
Halter Ferguson Financial Inc. Carmel, IN377KShares$825,0030.56% of portfolio
-
Geode Capital Management, LLC Boston, MA193KShares$421,7120.0% of portfolio
-
Black Rock Inc. New York, NY78.5KShares$171,9600.0% of portfolio
-
Centric Wealth Management68.2KShares$149,3990.05% of portfolio
About MAIA Biotechnology, Inc.
- Ticker MAIA
- Exchange
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,935,900
- Market Cap $23.9M
- Description
- MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company wa...